A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

Foot Surgery Clinical Trial

Official title:

A Randomized Controlled Trial Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01615939
• Other study ID #: STU00058306
• Secondary ID: STU00058306
• Status: Terminated
• Phase: Phase 4
• First received: June 7, 2012
• Last updated: October 1, 2015
• Start date: June 2012
• Est. completion date: January 2015

Study information

• Verified date: October 2015
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous infragluteal-parabiceps sciatic nerve catheter.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• all patients ( =18 and = 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.

Exclusion Criteria:

• history of hemostatic abnormalities

• chronic pain syndrome

• a foot deformity restricting normal foot movement

• severe liver or renal disease

• a preexisting neurologic disorder

• patient refusal to participate

• the presence of language barrier that prohibits proper communication with patient.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Foot Surgery

Intervention

Drug:
• Bupivacaine
Bupivacaine 0.625% with epinephrine 1:300,000
• Ropivacaine
0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.

Locations

Country	Name	City	State
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Temporary neurologic symptoms between groups		1 month	No
Secondary	satisfaction with anesthesia		1 month	No
Secondary	pain control		24-72hrs, 2weeks, 4weeks	No